Skip to main content
OpenTrials
Completed

NCT Number: NCT04259125

Evaluating the Role of Inflammation in Neonatal Epileptogenesis

The purpose of this study evaluate the relationship between inflammation and epilepsy in neonates with seizures after birth.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 day–4 day

Sex eligibility

All sexes

Study type

Observational

Primary location

UCSF Benioff Children's Hospital Oakland, Oakland, California, United States

Loading trial locations.

About this study

Seizures are a common symptom of neurologic dysfunction in the neonatal period, affecting more than 16,000 newborns in the United States per year. Over 25% of neonates with acute symptomatic seizures develop post- neonatal epilepsy (PNE), which is often resistant to medical therapies. There is a critical need to identify those patients most at risk for PNE and understand the mechanisms by which early seizures increase the propensity for recurrent seizures, in hopes of identifying novel therapeutic targets in this population. There is increasing evidence for the role of neuro-inflammation in the development of epilepsy. Levels of cytokines and micro-RNA (miRNA) may serve as markers of disease severity and have been implicated in epileptogenesis in animal models. The purpose of this study is to evaluate plasma cytokine and miRNA levels after neonatal-onset acute symptomatic seizures and determine their association with acute seizure severity and PNE.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

For participants in the acute symptomatic seizure group:

Inclusion criteria

  • Neonates <44 weeks corrected age at seizure onset
  • Seizures due to acute brain injury
  • Parent(s) who are English or Spanish literate (with assistance of interpreter)

Exclusion criteria

  • Neonates at risk for adverse outcome independent of seizures and underlying brain injury
  • Neonates with mild, temporary causes for seizures
  • Newborns with neonatal-onset epilepsy syndromes
  • Neonates who do not survive the initial hospital admission
  • Neonates will not be excluded based on race, ethnicity, gender or gestational age

For participants in the control group:

Inclusion criteria

  • Neonates that are born > 37 weeks and <44 weeks postmenstrual age at enrollment
  • Consultation by the pediatric neurology inpatient service due neonatal paroxysmal events, with normal neurologic examination and ultimate diagnosis of non-epileptic spells on continuous video-EEG (ordered for clinical purposes, not for research) OR consultation for hypoxic ischemic encephalopathy in neonates undergoing therapeutic hypothermia, with early exit from therapy owing to normal neurologic examination, normal continuous video-EEG and uncertain diagnosis of encephalopathy.
  • Neonates requiring neurologic consultation for mild hypoxic-ischemic encephalopathy (HIE) undergoing therapeutic hypothermia, with normal examination, cEEG, and neuroimaging upon rewarming.

Treatment and study plan

Blood draw

Diagnostic Test

Evaluation of plasma inflammatory markers including cytokines and micro-RNA.

Survey

Other

Regarding epilepsy and development.

Primary outcomes

  1. Seizure burden

    Time frame: At study entry

    Investigators will evaluate the seizure burden from the initial diagnostic electroencephalogram (EEG) after birth by determining the average number of seizures per hour.

  2. Percentage of participants diagnosed with epilepsy

    Time frame: 24 months of age

    The investigators will determine the proportion of participants who develop clinical and or electrographic seizures.

Secondary outcomes

  1. Percentage of participants diagnosed with epilepsy

    Time frame: 12 months of age

    The investigators will determine the proportion of participants who develop clinical and or electrographic seizures.

  2. Epilepsy Severity

    Time frame: 12 months of age

    The investigators will administer an investigator-developed questionnaire designed to define the frequency of seizures (monthly, weekly, daily, or greater than daily).

  3. Epilepsy Severity

    Time frame: 24 months of age

    The investigators will administer an investigator-developed questionnaire designed to define the frequency of seizures (monthly, weekly, daily, or greater than daily).

  4. Warner Initial Developmental Evaluation of Adaptive and Functional Skills (WIDEA-FS)

    Time frame: Assessment takes up to 15 minutes and will be conducted at 12 months of age

    The Warner Initial Developmental Evaluation of Adaptive and Functional Skills (WIDEA-FS) will be assessed at 12 months of age. The score ranges from 50 to 200 with higher scores associated with normal development.

  5. Warner Initial Developmental Evaluation of Adaptive and Functional Skills (WIDEA-FS)

    Time frame: Assessment takes up to 15 minutes and will be conducted at 24 months of age

    The Warner Initial Developmental Evaluation of Adaptive and Functional Skills (WIDEA-FS) will be assessed at 24 months of age. The score ranges from 50 to 200 with higher scores associated with normal development.

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Collaborators

  • Boston Children's Hospital
  • National Institute of Neurological Disorders and Stroke (NINDS)
  • UCSF Benioff Children's Hospital Oakland
  • University of Michigan

Registry information

Official study title

Neonatal Seizure Registry: The Role of Inflammation After Neonatal Seizures and Later Development of Epilepsy

Acronym: NSR-RISE

Important dates

Study start
2018
Primary completion
2024
Study completion
2025
First posted
Feb 6, 2020
Registry last updated
Jan 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.